Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Around the world, events are being held to mark Rare Disease Day (28 February 2025), with the aim of bringing attention to ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

The addition of Seladelpar to treat primary biliary cholangitis (PBC) complements the company’s existing liver portfolio and aligns with its quest to bring transformational medicines to patients.

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...

The addition of Seladelpar to treat primary biliary cholangitis (PBC) complements the company’s existing liver portfolio and aligns with its quest to bring transformational medicines to patients.

In the last few weeks, the FDA has granted accelerated approval to two drugs – Ipsen's Iqirvo (elafibranor) and Gilead Sciences' Livdelzi (seladelpar) – and Ipsen's drug was also recommended ...

Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – FOSTER CITY, CA, USA I February 20, 2025 I Gilead ...